Andecaliximab
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | ? |
Source | Chimeric (mouse/human) |
Target | gelatinase B |
Clinical data | |
Other names | GS-5745 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6396H9868N1680O2010S46 |
Molar mass | 143933.81 g·mol−1 |
Andecaliximab (INN;[1] development code GS-5745) is an experimental humanized monoclonal antibody designed for the treatment of cancer and inflammatory diseases.
This drug was developed by Gilead Sciences, Inc.[2]
Phase II and phase III trials for gastric cancer or gastroesophageal junction adenocarcinoma completed in 2019.
References
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- All stub articles
- Monoclonal antibody stubs
- Monoclonal antibodies